Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

McGill University

Status and phase

Unknown

Phase 2

Phase 1

Conditions

Cutaneous T-Cell Lymphoma

Treatments

Drug: Tazarotene

Study type

Interventional

Funder types

Other

Identifiers

NCT00779896

McG 0722

Details and patient eligibility

About

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.

Enrollment

15 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with Stage I-IIA CTCL must be at least 18 years of age with a skin biopsy prior to enrolment confirming the diagnosis of mycosis fungoides.

Exclusion criteria

Patients with Stage >IIA CTCL at the time of enrolment
Women who are pregnant or planning to get pregnant, or unable/unwilling to use adequate contraception
Patients who were treated with topical retinoid therapy in the past 3 months
Patients who received any systemic CTCL therapy or systemic corticosteroid therapy within 30 days of the study start date
Patients who were treated with systemic isotretinoin or bexarotene within 3 months prior to the study start date, systemic acitretin within 2 years prior to study start date